HBV-IN-56
HBV-IN-56 is an orally active HBsAg production inhibitor. HBV-IN-56 inhibits HBsAg production both in vitro and in vivo. HBV-IN-56 can be used for the research of chronic hepatitis B virus infection.
For research use only. We do not sell to patients.
- CAS No.: 2564693-71-4
- Formula: C20H20ClNO6S
- Molecular Weight:437.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
HBV-IN-56 (compound 31) potently inhibits HBsAg production in HBV-infected primary human hepatocytes, with an IC50 of 5 nM, and shows no cytotoxicity at concentrations up to 15,000 nM[1].
HBV-IN-56 (10-50 μM) exhibits extremely low off-target activity in safety assessment assays, including no significant kinase inhibition, CYP inhibition, hERG channel activity, or genotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | CL | Vss | T1/2 | Bioavailability |
|---|---|---|---|---|---|---|
| Mice[1] | 0.1 mg/kg | i.v. | 0.222 L/h/kg | 2.4 L/kg | 1.90 h | / |
| Mice[1] | 5 mg/kg | p.o. | / | / | 4.31 h | 49 % |
| Rat[1] | 0.1 mg/kg | i.v. | 0.08 L/h/kg | 0.506 L/kg | 4.47 h | / |
| Rat[1] | 10 mg/kg | p.o. | / | / | 9.10 h | 97 % |
| Dog[1] | 1 mg/kg | i.v. | 0.045 L/h/kg | 0.485 L/kg | 7.79 h | / |
| Dog[1] | 5 mg/kg | p.o. | / | / | 9.11 h | 86 % |
HBV-IN-56 (3-60 mg/kg; p.o.; 91 days) induces dose- and duration-dependent decreases in tail NCV and axonopathy in Sprague-Dawley rats, with no recovery observed 4 weeks after the end of administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male and female; 10 weeks old at study initiation, males 357-474 g, females 262-330 g)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 30 mg/kg; 60 mg/kg
-
Administration:p.o.; daily; 91 days
-
Result:Reduced caudal nerve conduction velocity (NCV) over the 13-week treatment period, with effects correlated to both dose and treatment duration.
Showed no recovery in caudal NCV in any dose group during the 4-week post-treatment recovery period and detected axonopathy via histological analysis at all dose levels.
Chemical Information
-
CAS No. 2564693-71-4
-
Molecular Weight 437.89
-
Formula C20H20ClNO6S
-
SMILES
ClC1=CC(C2=C(C3)C=C(C(N2C4CC4)=O)C(O)=O)=C(C=C1OCC(C)C)S3(=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HBV-IN-56 Related Classifications
HY-181348 Related Classifications
Powered by Bioz